Fig. 3.

IL12RB2 knockdown in B16F0 decreases the survival benefit of IL-12. a Flow cytometry was used to compare IL12RB2 expression in B16F0 cells edited using a CRISPR/Cas9 construct to knockdown IL12RB2 (IL12RB2 KD – black histogram) with wild-type (wt – red histogram) B16F0 cells. Unstained B16F0 cells were used as a negative control (grey shaded histogram). Cell viability was assessed using an ATPlite assay in wild-type (b) and IL12RB2 KD (c) B16F0 cells following treatment with the indicated concentration of imatinib with or without pre-treatment with 100 ng/ml of IL-12. Results are summarized by a bar graph (ave +/- stdev) overlaid with individual results (x’s) that represent at least 5 independent biological replicates for each condition. Statistical significance in the difference in viability upon IL-12 treatment for a given imatinib concentration was assessed using a two-tailed homoscedastic t-Test, where ** indicates a p-value <0.005 and * indicates a p-value <0.05